Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR
Status:
Terminated
Trial end date:
2016-05-23
Target enrollment:
Participant gender:
Summary
To compare the effect of ticagrelor versus aspirin on the change in peak walking time,
evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in
patients with peripheral artery disease who have undergone endovascular revascularization for
moderate to severe claudication or ischemic rest pain.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Collaborator:
CPC Clinical Research
Treatments:
Aspirin Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Ticagrelor